Payne K - Search Results

1

A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice.

Jani M, Gavan S, Chinoy H, Dixon WG, Harrison B, Moran A, Barton A, Payne K. Jani M, et al. Among authors: payne k. Rheumatology (Oxford). 2016 Dec;55(12):2131-2137. doi: 10.1093/rheumatology/kew292. Epub 2016 Aug 29. Rheumatology (Oxford). 2016. PMID: 27576368 Free PMC article.

2

Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?

Elliott RA, Hooper L, Payne K, Brown TJ, Roberts C, Symmons D. Elliott RA, et al. Among authors: payne k. Rheumatology (Oxford). 2006 May;45(5):606-13. doi: 10.1093/rheumatology/kei241. Epub 2005 Dec 20. Rheumatology (Oxford). 2006. PMID: 16368733 Review.

3

Cost-effectiveness analysis in pharmacogenomics.

Payne K, Shabaruddin FH. Payne K, et al. Pharmacogenomics. 2010 May;11(5):643-6. doi: 10.2217/pgs.10.45. Pharmacogenomics. 2010. PMID: 20415553 Review.

4

Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Heather EM, Payne K, Harrison M, Symmons DP. Heather EM, et al. Among authors: payne k. Pharmacoeconomics. 2014 Feb;32(2):109-34. doi: 10.1007/s40273-013-0120-z. Pharmacoeconomics. 2014. PMID: 24338344 Review.

5

Economics of stratified medicine in rheumatoid arthritis.

Gavan S, Harrison M, Iglesias C, Barton A, Manca A, Payne K. Gavan S, et al. Among authors: payne k. Curr Rheumatol Rep. 2014 Dec;16(12):468. doi: 10.1007/s11926-014-0468-x. Curr Rheumatol Rep. 2014. PMID: 25366935 Review.

6

Cost-effectiveness analyses of genetic and genomic diagnostic tests.

Payne K, Gavan SP, Wright SJ, Thompson AJ. Payne K, et al. Nat Rev Genet. 2018 Apr;19(4):235-246. doi: 10.1038/nrg.2017.108. Epub 2018 Jan 22. Nat Rev Genet. 2018. PMID: 29353875 Review.

7

The economic case for precision medicine.

Gavan SP, Thompson AJ, Payne K. Gavan SP, et al. Among authors: payne k. Expert Rev Precis Med Drug Dev. 2018 Jan 8;3(1):1-9. doi: 10.1080/23808993.2018.1421858. eCollection 2018. Expert Rev Precis Med Drug Dev. 2018. PMID: 29682615 Free PMC article.

8

Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies.

Gavan SP, Lu CY, Payne K. Gavan SP, et al. Among authors: payne k. J Pers Med. 2019 May 21;9(2):28. doi: 10.3390/jpm9020028. J Pers Med. 2019. PMID: 31117188 Free PMC article.

9

Factors that influence rheumatologists' anti-tumor necrosis factor alpha prescribing decisions: a qualitative study.

Gavan SP, Daker-White G, Payne K, Barton A. Gavan SP, et al. Among authors: payne k. BMC Rheumatol. 2019 Dec 19;3:47. doi: 10.1186/s41927-019-0097-0. eCollection 2019. BMC Rheumatol. 2019. PMID: 31891115 Free PMC article.

10

Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations.

Gavan S, Bruce I, Payne K. Gavan S, et al. Among authors: payne k. Lupus Sci Med. 2020 Jul;7(1):e000350. doi: 10.1136/lupus-2019-000350. Lupus Sci Med. 2020. PMID: 32723809 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

841 results

Search Page

Filters